Your NEJM Group Today: Aortic Valve Clinical Pearl, Chikungunya Vaccine, Phoenix Hospitalist Opportunity (FREE)

By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news

Related Links:

In conclusion, green synthesized nano-biomaterials can act as good antiviral agents. These nano-biomaterials can further be processed for formulation of effective and promising nanomedicines against CHIKV and other similar viruses which are a threat to human health. PMID: 32409081 [PubMed - in process]
Source: Appl Human Sci - Category: Physiology Authors: Tags: Mater Sci Eng C Mater Biol Appl Source Type: research
ang L Abstract Despite the worldwide re-emergence of the chikungunya virus (CHIKV) and the high morbidity associated with CHIKV infections, there is no approved vaccine or antiviral treatment available. We here aim to identify the target of a novel class of CHIKV inhibitors i.e. CHVB series. CHVB compounds inhibit the in vitro replication of CHIKV isolates with 50% effective concentrations in the low micromolar range. A CHVB-resistant variant (CHVBres) was selected that carried two mutations in the gene encoding nsP1 (responsible for viral RNA capping), one mutation in nsP2 and one mutation in nsP3. Reverse geneti...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
In this study, 48,750 small molecules were screened in silico for their ability to bind to the ADP-ribose binding site of the CHIKV nsP3 macro domain. From this in silico analysis, 12 molecules were selected for in vitro analysis using a CHIKV subgenomic replicon in Huh-7 cells. Cell viability and CHIKV replication were evaluated and molecules C5 and C13 demonstrated 53 and 66% inhibition of CHIKV replication, respectively. By using a CHIKV-Dual luciferase replicon contain two reporter genes, we also demonstrated that the treatment with either compounds are probably interfering in the early replication rather than after RN...
Source: Acta Tropica - Category: Infectious Diseases Authors: Tags: Acta Trop Source Type: research
NEW YORK (Reuters Health)—A new chikungunya virus-like-particle vaccine appears to be safe and immunogenic, according to results from a phase 2 trial. “The phase 2 safety, tolerability and immunogenicity were similar to the data seen in an earlier phase 1 study,” Grace L. Chen, MD, of the National Institutes of Health Vaccine Research Center, Bethesda,... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions chikungunya CHIKV polyarthritis vaccine Source Type: research
We report a traumatic injury in a 2-year-old boy who entered Madeira River. The use of traditional methods to treat the injury and his incomplete vaccination history reflect the weakness of the health system. Further, the fact that it was the second time that such an incident had occurred in the locality in 3 weeks during the dry season suggests that this could be a frequent occurrence during this period.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
We report a traumatic injury in a 2-year-old boy who entered Madeira River. The use of traditional methods to treat the injury and his incomplete vaccination history reflect the weakness of the health system. Further, the fact that it was the second time that such an incident had occurred in the locality in 3 weeks during the dry season suggests that this could be a frequent occurrence during this period.
Source: Revista da Sociedade Brasileira de Medicina Tropical - Category: Tropical Medicine Source Type: research
Abstract Dengue is the most important infectious disease in the world and is a severe public health problem. The chikungunya is an arbovirus, in many cases, increased, which is transmitted by the same transmitter dengue vector, Aedes aegypti. The symptoms of both diseases are similar, and infections can be lethal. Although there is no preventive vaccine against any of the two diseases, therefore, it is extremely important to control the mosquito. The eggs of A. aegypti are very resistant and hatch into larvae, which later give rise to mosquitoes in any container with water. Natural plant extracts have come from ac...
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Tags: Environ Sci Pollut Res Int Source Type: research
cute;lez-Santamaría The alphaviruses Chikungunya (CHIKV), Mayaro (MAYV), Una (UNAV), and the flavivirus Zika (ZIKV) are emerging or re-emerging arboviruses which are responsible for frequent epidemic outbreaks. Despite the large impact of these arboviruses on health systems, there are no approved vaccines or treatments to fight these infections. As a consequence, there is an urgent need to discover new antiviral drugs. Natural products are a rich source of compounds with distinct biological activities, including antiviral properties. Thus, we aimed to explore the potential antiviral activity of Ginkgolic acid a...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Editor's Summary by Angel Desai, JAMA Fishebein Fellow, for the Journal of the American Medical Association April 14, 2020 issue
Source: JAMA: This Week's Audio Commentary - Category: General Medicine Authors: Source Type: podcasts
This clinical trial tested whether the chikungunya virus –like particle vaccince was safe for participants living in chikungunya endemic areas.
Source: JAMA - Category: General Medicine Source Type: research
More News: Chikungunya | Hospitalists | Primary Care | Vaccines